Atrasentan in Patients With IgA Nephropathy

Running, not enrolling · Phase 3 · Has a placebo group

Conditions studied: IgA Nephropathy, Immunoglobulin A Nephropathy

In brief

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

Key facts

Study ID

NCT04573478

Run by

Novartis Pharmaceuticals

People needed

404

Starts

2020-12-11

Expected to finish

2028-04-14

Last updated by the study team

2026-06-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Double-Blind period:
• Biopsy-proven IgA nephropathy.
• Receiving a maximally tolerated dose of RAS inhibitor therapy (ACEi or ARB) that has been stable for at least 12 weeks. Exceptions from this requirement will be made for subjects who are unable to tolerate RAS inhibitor therapy.
• Total urine protein ≥1 g/day as measured via 24-hour urine collection by central laboratory at Screening.
• eGFR of at least 30 mL/min/1.73 m\^2 at Screening based on the CKD-EPI equation.
• Willing and able to provide informed consent and comply with all study requirements.
• SGLT2i Stable Stratum Only - Receiving a stable dose of an SGLT2i (per Investigator choice) in addition to a maximally tolerated and optimized dose of a RAS inhibitor that has been stable for at least 12 weeks prior to Screening.
• All fertile men and WOCBP who engage in heterosexual intercourse must be willing to abide with highly effective forms of contraception, as specified in the protocol, throughout the study and for 1 month afterward. In WOCBP, use of contraceptive agents must have been started at least 1 month prior to Baseline.
• Open-Label Period:
• Willing and able to provide informed consent and comply with all OL extension study visits and study procedures.
• Completed treatment through Week 132 and completed the Week 136 visit.
• All fertile men and WOCBP who engage in heterosexual intercourse must be willing to abide with highly effective forms of contraception, as specified in the protocol, throughout the study and for 1 month afterward. In WOCBP, use of contraceptive agents must have been continued after completing the double-blind portion of the study.
• Substudy:
• Subjects must meet ALL inclusion criteria to be enrolled.
• Subjects who provided written informed consent prior to initiation of any substudy-specific activities/procedures and are willing to comply with all substudy visits and substudy procedures.
• Completion of OL extension treatment through Week 48 visit or treated with atrasentan long enough to sufficiently determine its efficacy as per clinical judgement of the Principal Investigator.
• Stable on a maximally tolerated dose of ACEi and/or ARB for at least 12 weeks prior to substudy screening visit.
• All fertile men and WOCBP who engage in heterosexual intercourse must be willing to abide with highly effective forms of contraception, as specified in the protocol

You may not qualify if…

• Double-blind period:
• Concurrent diagnosis of another cause of chronic kidney disease including diabetic kidney disease or another primary glomerulopathy.
• Clinical diagnosis of nephrotic syndrome.
• BNP value of > 200 pg/mL at Screening.
• Platelet count <80,000 per μL at Screening.
• History of organ transplantation (subjects with history of corneal transplant are not excluded).
• Use of systemic immunosuppressant medications.
• Hemoglobin below 9 g/dL at Screening or prior history of blood transfusion for anemia within 3 months of Screening.
• Open-label period:
• eGFR < 25 mL/min/1.73m\^2 or evidence of rapidly decreasing eGFR, including unrecovered acute kidney injury or expected to require renal replacement therapy within 3 months
• BNP value of > 200 pg/mL at OL Screening.
• Platelet count < 80,000 per μL at OL Screening.
• Hemoglobin below 9 g/dL at OL screening or prior history of blood transfusion for anemia within 3 months of OL Screening.
• Substudy:
• Subjects must meet NONE of the following exclusion criteria to be enrolled.
• Participants who are not receiving atrasentan at the time of substudy screening visit in the ALIGN OL extension study phase or had atrasentan interruption for longer than 2 weeks within last 24 weeks of substudy screening visit.
• ALIGN OL extension participants with insufficient compliance defined as less than 70%
• Plan to receive any investigational agent (other than atrasentan or zigakibart) or approved treatment for IgAN (other than a RAS inhibitor or SGLT2i). Other ETA receptor antagonists will not be allowed during substudy extension.
• eGFR < 25 mL/min/1.73m2 or evidence of rapidly decreasing eGFR, including unrecovered acute kidney injury or expected to require renal replacement therapy within 3 months
• Ongoing treatment-related SAE or ongoing related severe AESI.
• Clinical suspicion of rapidly progressive glomerulonephritis (RPGN).
• Received a live vaccination within 12 weeks prior to first substudy treatment administration in the substudy or plan to have a live vaccination within 6 months after the last dose of substudy treatment.
• BNP value of > 200 pg/mL at substudy Screening.
• Blood pressure >150 mmHg systolic or >95 mmHg diastolic at screening
• Known history of heart failure or conditions relating to fluid overload.

Where it is running

• Comprehensive Research Institute — Alhambra, California, United States
• Kidney Disease Medical Group — Glendale, California, United States
• Stanford University — Stanford, California, United States
• University of Florida — Gainesville, Florida, United States
• GA Nephrology Associates — Lawrenceville, Georgia, United States
• NANI Research, LLC — Hinsdale, Illinois, United States
• NANI Research, LLC — Fort Wayne, Indiana, United States
• University of Louisville Physicians- Kidney Disease Program — Louisville, Kentucky, United States
• Tufts Medical Center — Boston, Massachusetts, United States
• Intermed Consultants — Minneapolis, Minnesota, United States
• Pelican Point Dialysis - DaVita Clinical Research — Las Vegas, Nevada, United States
• Capital District Renal Physicians — Clifton Park, New York, United States
• Mountain Kidney and Hypertension Associates — Asheville, North Carolina, United States
• Brookview Hills Research Associates, LLC — Winston-Salem, North Carolina, United States
• Lehigh Valley Hospital — Bethlehem, Pennsylvania, United States
• University of Pennsylvania — Philadelphia, Pennsylvania, United States
• Liberty Research Center — Dallas, Texas, United States
• El Paso Kidney Specialists — El Paso, Texas, United States
• Nephrology Associates Of Northern Virginia — Fairfax, Virginia, United States
• Swedish Health Services — Seattle, Washington, United States
• Centro Médico Ce.Re.Ca — San Luis, San Luis Province, Argentina
• CEMIC — Buenos Aires, Argentina
• Hospital Britanico de Buenos Aires — Buenos Aires, Argentina
• Clinica de Nefrologia Urologia y Enf. Cardiovasculares — Santa Fe, Argentina
• University of Alabama at Birmingham — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.